Immunotherapy and radiotherapy for metastatic cancers

Area of Science:

• Oncology
• Radiation Oncology
• Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) are a breakthrough therapy for metastatic cancers.
• Radiotherapy (RT) is increasingly used for metastatic disease, including stereotactic ablative radiotherapy (SABR) for oligometastases and palliative care.
• Many patients with metastatic cancer are candidates for both ICIs and RT, necessitating guidance on combined treatment.

Purpose of the Study:

• To review the existing literature on the safety and efficacy of combining radiotherapy with immune checkpoint inhibitors in metastatic cancer.
• To address key questions regarding the impact of RT dose, timing, and site on combined treatment outcomes.
• To highlight ongoing research into the local and systemic benefits of this therapeutic combination.

Main Methods:

• Literature review of studies investigating combined radiotherapy and immunotherapy in metastatic cancer.
• Focus on safety outcomes, including radiation-induced pneumonitis and radionecrosis.
• Analysis of factors such as radiation dose, treatment timing, and anatomical site.

Main Results:

• The review addresses safety concerns associated with combined treatment, specifically pneumonitis and radionecrosis.
• It explores how radiation dose, timing, and location influence treatment outcomes.
• Ongoing research is investigating the potential synergistic effects of combining these modalities.

Conclusions:

• Combined radiotherapy and immunotherapy represents a promising approach for managing metastatic cancers.
• Further research is crucial to optimize treatment protocols and maximize patient benefit.
• Understanding the interplay between radiation and immunotherapy is key to advancing cancer care.